References
- Novelli M, Rossi S, Rodriguez-Justo M et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumors. Histhopathology57, 259–270 (2010).
- Rossi S, Gasparotto D, Toffolatti L et al. Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size. Am. J. Surg. Pathol.34, 1480–1491 (2010).
- Demetri GD, Benjamin RS, Blanke CD et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST) – update of the NCCN clinical practice guidelines. J. Natl Compr. Canc. Netw.5(Suppl. 2), S1–S29; quiz S30 (2007).
- Gronchi A, Judson I, Nishida T et al. Adjuvant treatment of GIST with imatinib: solid ground or still quicksand?. A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS). Eur. J. Cancer45(7), 1103–1106 (2009).
- Casali PG, Blay JY; ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.21(Suppl. 5), v98–v102 (2010).
- Joensuu H, Vehtari A, Riihimaki J et al. Risk of recurrence of gastrointestinal stromal tumours after surgery: an analysis of pooled population-based cohorts. Lancet Oncol.13, 265–274 (2012).
- Dematteo RP, Ballman KV, Antonescu CR et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet373(9669), 1097–1104 (2009).
- Le Cesne A, Ray-Coquard I, Bui BN et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised Phase 3 trial. Lancet Oncol.11(10), 942–949 (2010).
- George S, Blay JY, Casali PG et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur. J. Cancer45(11), 1959–1968 (2009).
- Gounder MM, Maki RG. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Cancer Chemother. Pharmacol.67(Suppl. 1), S25–S43 (2011).
- Chibon F, Lagarde P, Salas S et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat. Med.16(7), 781–787 (2010).
- Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol.8, 595–602 (2007).
- Scurr M. Histology-driven chemotherapy in soft tissue sarcomas. Curr. Treat. Options Oncol.12(1), 32–45 (2011).
- Wagner AJ, Malinowska-Kolodziej I, Morgan JA et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J. Clin. Oncol.28(5), 835–840 (2010).
- Ray-Coquard I, Le Cesne A. Role for maintenance therapy in managing sarcoma. Cancer Treat. Rev. doi:10.1016/j.ctrv.2011.07.003 (2011) (Epub ahead of print).
- Taylor BS, Barretina J, Maki RG et al. Advances in sarcoma genomics and new therapeutic targets. Nat. Rev. Cancer11(8), 541–557 (2011).
- Gronchi A, Lo Vullo S, Fiore M et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. J. Clin. Oncol.27(1), 24–30 (2009).
- Garbay D, Le Cesne A, Penel N et al. Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann. Oncol.23(1), 182–186 (2012).
- Salas S, Dufresne A, Bui B. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J. Clin. Oncol.29(26), 3553–3558 (2011).
- Buwalda J, Schouwenburg PF, Blank LE et al. A novel local treatment strategy for advanced stage head and neck rhabdomyosarcomas in children: results of the AMORE protocol. Eur. J. Cancer39(11), 1594–1602 (2003).
Websites
- European Society for Medical Oncology. www.esmo.org
- European Organisation for Research and Treatment of Cancer. www.eortc.org